Acer Therapeutics

The company entered a research collaboration with NCATS, part of NIH, in 2020 to develop emetine hydrochloride as a potential treatment for SARS-CoV-2 infection.

ACER-801 (osanetant) is an investigational non-hormonal NK3R antagonist being developed as a potential treatment for vasomotor symptoms, PTSD and prostate cancer.

The page describes Ehlers-Danlos syndrome as an inherited disorder caused by mutations affecting collagen or proteins that interact with collagen.

The company intends, subject to additional capital, to explore OLPRUVA lifecycle opportunities in UCD patients and disorders including MSUD and pyruvate dehydrogenase complex deficiency.

Acer Therapeutics announced presentation and publication of results from a pilot study evaluating antihypertensive therapy and clinical events in patients with vascular Ehlers-Danlos syndrome.

The page lists studies on OLPRUVA/ACER-001, including research on treatment preferences for urea cycle disorders and taste-masked sodium phenylbutyrate.

Acer’s mission is to develop accessible therapies for people affected by serious rare and life-threatening diseases with significant unmet medical needs.

Mr. Schelling is Acer’s president and chief executive officer. He founded Acer in 2013 and Censa Pharmaceuticals in 2015; Censa was sold to PTC Therapeutics in 2020.

Mr. Aselage has more than 30 years of pharmaceutical and biotechnology experience. He led Travere Therapeutics, formerly Retrophin, as chief executive officer from 2014 to 2019 and previously held executive roles at BioMarin.

Mr. Kneeland joined Acer as VP Finance, Controller in 2017 after more than 20 years in corporate finance leadership. He previously was VP Finance at TechTarget, Inc.

Mr. Klopp joined Acer as vice president of manufacturing in 2018 and became chief technical officer in 2019. He has more than 18 years of biopharmaceutical experience in drug development, process development and contract manufacturing.

Acer develops and commercializes therapies for rare and life-threatening diseases. In the U.S., OLPRUVA (sodium phenylbutyrate) is approved for certain urea cycle disorders involving CPS, OTC or AS deficiencies.

The page provides contact information for adverse event reporting, medical inquiries, investors, media, business development and human resources, as well as Acer’s Newton office address.